Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Evaluation of Safety, Tolerability, and Efficacy of BI 730357 in Patients With Moderate-to-severe Plaque Psoriasis

NCT03635099 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT03635099
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03635099 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Evaluation of Safety, Tolerability, and Efficacy of BI 730357 in Patients With Moderate-to-severe Plaque Psoriasis
Lead sponsor
Boehringer Ingelheim
Phase
Phase 2
Overall status
Completed
Start date
September 17, 2018
Completion date
May 26, 2021
Enrollment
274 (actual)
Sites
34

Conditions

As the registry lists them; a condition with its own page is linked.

psoriasis